CardiaBeats European roll-out continues

By Alex McNally

- Last updated on GMT

Related tags: Atherosclerosis, Cholesterol

Enzymotec has taken another step in rolling out its CardiaBeat
heart health ingredient, signing an agreement with Genexo to see it
enter the Polish market.

The Israeli firm has already signed deals to see the ingredient launch in the India and Australian market, and has said it will expand further into Europe by the end of the year. The deal with Genexo signals continued growth for Enzymotec, which last month announced it will build a new 200,000 sq foot research and development centre to meet "growing demand." The ingredient is an extension of Enzymotec's functional oil formulation MultOil, which has been shown to potentially reduce the risk for coronary heart disease through preventing and controlling oxidative stress, reducing total cholesterol and triglyceride levels and inhibiting the atherosclerotic plaque formation cascade. The means it tackles more heart health indicators than many ingredients on the market, which look only after cholesterol management. CardiaBeat also enhances the impact of plant sterols and omega-3s on cardiovascular disease (CVD) risk reduction, the firm added. Marketing manager Michal Haim-Bravman said: "I am proud that Genexo have found CardiaBeat as a complementary dietary supplement to the current drug line they have for CVD. Signing of this agreement … is an important milestones in our sales and marketing strategy for CardiaBeat in Europe. We expect to finalize more strategic agreements before the end of this year." ​ According to several market reports published in the last three years, the demand for dietary supplements in Poland is growing due to increasing willingness to self-medicate and the awareness for CVD and its prevention, Enzymotec said. Indeed, a survey in April by Poland-based market research company PMR said a rise in sales of dietary supplements was brought on by society's wish to live a healthier life. Genexo is a private Polish pharmaceutical company offering products for the diagnosis, treatment and prevention of metabolic diseases including diabetes, hypercholesterolemia, and obesity. In August Enzymotec said a new R&D centre, due to be completed by the end of the year, will help the company to meet increasing demand for its products. Enzymotec said yesterday that the building was needed to answer a rise in demand for its product, particularly GPC and Krill Oil, which could not be handled by its current facilities. The hub will also be used to produce its "brain energizer" ingredient Sharp PS which is a form of phosphatidylserine, and CardiaBeat.

Related news

Show more

Related products

show more

Resveratrol and Sports Nutrition: A Winning Combo

Resveratrol and Sports Nutrition: A Winning Combo

Evolva | 18-Oct-2019 | Technical / White Paper

In addition to physical activity, research indicates that resveratrol can be a key ingredient for top sports performance. Not only has resveratrol been...

Vitamin K2 Success Stories: NattoPharma

Vitamin K2 Success Stories: NattoPharma

NattoPharma USA, Inc. | 23-Sep-2019 | Case Study

Partnership means companies are bound to the process – from formulation and testing to marketing and meeting demand. That is what companies selecting MenaQ7®...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars